Yi-Chien Tsai, Jing-Rong Huang, Jing-Yan Cheng, Jin-Jin Lin, Jung-Tung Hung, Yih-Yiing Wu, Kun-Tu Yeh and Alice L. Yu
Globo H, a hexasaccharide initially identified as a ceramide-linked glycolipid from human breast cancer cell line MCF-7, is over-expressed on the surface of many common cancers, but its function is unknown. Here we demonstrated the uptake of globo H ceramide (GHCer) by human peripheral blood mononuclear cells (PBMC) upon co-culture with MCF-7 cells. Significantly, the expression of globo H on tumor-infiltrating lymphocytes was observed in 61% of globo H positive breast cancer tissues. Addition of synthetic GHCer to human PBMC, mouse splenocytes or purified CD4+ T cells inhibited their proliferative response to anti-CD3/CD28 to 60 ± 1%, 50 ± 7% and 62 ± 5% of control, respectively, and reduced the secretion of IL-2, IFN-γ and IL-4. GHCer also significantly suppressed the proliferation of splenocytes or purified CD19+ B cells to 45 ± 10% and 26 ± 3% of control in response to LPS or LPS + IL4 +CD40 ligand and their IgM production to 12 ± 5% and, 8 ± 3%, and IgG to 34 ± 9%, 35 ± 5%, respectively, with neglible induction of plasma cells. Ceramide displayed no such inhibitory effects. On the other hand, GHCer failed to raise the number of regulatory T cells, or their expression of FOXP3/CTLA4, nor did it increase apoptosis. Notably, GHCer significantly suppressed the Notch1 signaling during activation of human PBMC and murine T and B cells. Furthermore, GHCer upregulated the expression of ID3 and itch by 2.1±0.2 and 4.7 ± 0.4 fold, respectively, leading to ID3-dependent downregulation of Notch1 and itch-mediated Notch1 degradation. These results provide the first evidence for GHCer to facilitate the escape of cancer cells from immune surveillance.
PDFShare this article
Cancer Science & Therapy received 3968 citations as per Google Scholar report
